SEQUENT

Sequent Scientific Share Price

₹177.97 -3.95 (-2.17%)

19 May, 2025 13:18

SIP TrendupStart SIP in SEQUENT

Start SIP

Performance

  • Low
  • ₹177
  • High
  • ₹182
  • 52 Week Low
  • ₹92
  • 52 Week High
  • ₹241
  • Open Price₹182
  • Previous Close₹182
  • Volume586,928

Investment Returns

  • Over 1 Month + 20.79%
  • Over 3 Month + 20.42%
  • Over 6 Month -4.7%
  • Over 1 Year + 52.7%
SIP Lightning

Smart Investing Starts Here Start SIP with Sequent Scientific for Steady Growth!

Invest Now

Sequent Scientific Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 241.8
  • PEG Ratio
  • 2.1
  • Market Cap Cr
  • 4,455
  • P/B Ratio
  • 6.6
  • Average True Range
  • 8.67
  • EPS
  • 0.51
  • Dividend Yield
  • 0
  • MACD Signal
  • 5.22
  • RSI
  • 73.28
  • MFI
  • 86.88

Sequent Scientific Financials

Sequent Scientific Technicals

EMA & SMA

Current Price
₹177.97
-3.95 (-2.17%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹159.04
  • 50 Day
  • ₹153.69
  • 100 Day
  • ₹157.26
  • 200 Day
  • ₹157.49

Resistance and Support

179.5 Pivot Speed
  • R3 203.68
  • R2 194.81
  • R1 188.37
  • S1 173.06
  • S2 164.19
  • S3 157.75

What's your outlook on Sequent Scientific?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sequent Scientific Ltd. is a leading animal health company in India, specializing in the manufacturing of veterinary pharmaceuticals, including APIs and formulations. It serves global markets with a strong focus on quality, compliance, and innovation.

Sequent Scientific has an operating revenue of Rs. 1,510.87 Cr. on a trailing 12-month basis. An annual revenue de-growth of -3% needs improvement, Pre-tax margin of -4% needs improvement, ROE of -5% is poor and needs improvement. The company has a reasonable debt to equity of 22%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 200DMA and around 20% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 28 which is a POOR score indicating inconsistency in earnings, a RS Rating of 83 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 87 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sequent Scientific Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-20 Audited Results & Final Dividend
2025-02-11 Quarterly Results
2024-11-13 Quarterly Results
2024-08-14 Quarterly Results
2024-05-15 Audited Results & Final Dividend
Date Purpose Remarks
2021-09-10 FINAL Rs.0.50 per share(25%)Final Dividend
View More

Sequent Scientific F&O

Sequent Scientific Shareholding Pattern

52.61%
10.22%
6.05%
23.43%
7.69%

About Sequent Scientific

  • NSE Symbol
  • SEQUENT
  • BSE Symbol
  • 512529
  • Managing Director & CEO
  • Mr. Rajaram Narayanan
  • ISIN
  • INE807F01027

Similar Stocks to Sequent Scientific

Sequent Scientific FAQs

Sequent Scientific share price is ₹177 As on 19 May, 2025 | 13:04

The Market Cap of Sequent Scientific is ₹4454.6 Cr As on 19 May, 2025 | 13:04

The P/E ratio of Sequent Scientific is 241.8 As on 19 May, 2025 | 13:04

The PB ratio of Sequent Scientific is 6.6 As on 19 May, 2025 | 13:04

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23